Emergent BioSolutions Inc.
NYSE:EBSBiotechnology
-$0.21 today
- Market cap
- $282.78M
- Beta
- 2.33
- P/E (TTM)
- -47.9
- EPS (TTM)
- -$0.17
Volume 0.82M
Average 0.78M
EBS Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Emergent BioSolutions Inc.NYSE: EBS
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue declines year over year
Q1 FY2026 cost of revenue of $88.5M fell 16.3% year over year, ahead of the -38.7% change in trailing-twelve-month cost of revenue. Sequentially, it fell 13.3% from the prior quarter. Over 3 fiscal years it compounded at -15.3% a year.
Context
- Cost of revenue amounted to 52.8% of revenue in FY2025, down 11.2 pp from a year earlier.
- Cost of revenue increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -16.3% holds above the trailing-twelve-month pace of -38.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 392.3M USD
- Year-over-year change
- -41.3%
- 4-year CAGR
- -20.5%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 392.3M | -41.3% |
| FY2024 | 2024-12-31 | 668.2M | -3.1% |
| FY2023 | 2023-12-31 | 689.3M | +7.0% |
| FY2022 | 2022-12-31 | 644.5M | -34.3% |
| FY2021 | 2021-12-31 | 980.4M | — |
Cost of Revenue vs competitors
How EBS compares with its peers on the latest reported figures
- Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -38.7% is the lowest of 7, against a peer median of +11.2%.
- Cost of revenue amounts to 55.6% of revenue for EBS, versus a peer median of 35.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$682.57M CAD | +0.2% | +6.3% | 72.8% | |
| LTM Mar 2026 | $376M USD | -38.7% | -15.3% | 55.6% | |
| LTM Mar 2026 | $151.94M USD | +37.2% | +9.4% | 29.6% | |
| LTM Mar 2026 | $146.39M USD | +62.5% | +68.6% | 35.0% | |
| LTM Mar 2026 | $32.49M USD | +15.1% | +41.7% | 34.6% | |
| LTM Mar 2026 | $30.8M USD | — | — | 53.2% | |
| LTM Mar 2026 | $19.82M USD | -5.8% | +123.9% | 6.6% | |
| LTM Mar 2026 | $18.37M USD | +7.2% | -4.0% | 36.5% | |
| LTM Mar 2026 | $306K USD | — | — | — | |
| LTM Mar 2026 | $55K USD | — | — | — | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| Peer median (excluding EBS) | — | +11.2% | +25.6% | 35.0% | |
Competitors are the stored peer set for EBS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.77B | 1.12B | 1.05B | 1.04B | 742.9M |
| Cost of Revenue | 980.4M | 644.5M | 689.3M | 668.2M | 392.3M |
| Gross Profit | 793.2M | 473M | 360M | 375.4M | 350.6M |
| Gross Margin | 44.7% | 42.3% | 34.3% | 36.0% | 47.2% |
| Research & Development | 235.2M | 188.3M | 111.4M | 70.7M | 53.8M |
| Selling, General & Admin | 348.7M | 339.5M | 356.7M | 298.7M | 186.6M |
| Operating Expenses | 451.8M | 643M | 1.09B | 484.1M | 240.4M |
| Depreciation & Amortization | 118.2M | 125M | 121.1M | 105.6M | 98.3M |
| EBITDA | 504.2M | 15.7M | (47M) | 53.4M | 240.4M |
| EBITDA Margin | 28.4% | 1.4% | -4.5% | 5.1% | 32.4% |
| Operating Income | 341.4M | (170M) | (726.4M) | (108.7M) | 110.2M |
| Operating Margin | 19.2% | -15.2% | -69.2% | -10.4% | 14.8% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 34.5M | 37.3M | 87.9M | 71M | 59.3M |
| Other Income / Expenses | (38.2M) | (49M) | (4.8M) | (34.2M) | (27.4M) |
| Income Before Tax | 303.2M | (219M) | (731.2M) | (142.9M) | 82.8M |
| Pre-Tax Margin | 17.1% | -19.6% | -69.7% | -13.7% | 11.1% |
| Income Tax Expense | 83.7M | (7.4M) | 29.3M | 47.7M | 30.2M |
| Net Income | 219.5M | (211.6M) | (760.5M) | (190.6M) | 52.6M |
| Net Margin | 12.4% | -18.9% | -72.5% | -18.3% | 7.1% |
| EPS (Basic) | 4.10 | (4.22) | (14.85) | (3.60) | 0.98 |
| EPS (Diluted) | 4.06 | (4.22) | (14.85) | (3.60) | 0.93 |
| Weighted Avg Shares | 53.5M | 50.1M | 51.2M | 53M | 53.5M |
| Weighted Avg Shares (Diluted) | 54.1M | 50.1M | 51.2M | 53M | 56.7M |
Emergent BioSolutions Inc.
NYSE:EBS
Intrinsic Alpha fair value
Locked
Current Price
$5.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.